Disseminated nasal-type natural killer/T-cell lymphoma in a child: A case report

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 5, 2009, Pages 362-366

  Pellier, Isabelle ^a   N'Golet, Lydie ^a   Rachieru, Petronela ^a   Rousselet, Marie Christine ^a   Geneviève, Franck ^a   Moles, Marie Pierre ^a   Hermine, Olivier ^b   Rialland, Xavier ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Children; Leukemia; Nasal type NK T cell lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; VINDESINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORY TEST; LYMPHOCYTE PROLIFERATION; NATURAL KILLER T CELL; NK T CELL LYMPHOMA; ORAL BIOPSY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SEROLOGY; THORAX RADIOGRAPHY; TONSIL; BIOPSY; DRUG RESISTANCE; FATALITY; NATURAL KILLER CELL; NOSE TUMOR; PATHOLOGY; T CELL LYMPHOMA; TONSIL TUMOR;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; NOSE NEOPLASMS; TONSILLAR NEOPLASMS;

EID: 66149156558     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181998346     Document Type: Article

References (35)

1. Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. Hematology (Am Soc Hematol Educ Program). 2001;259-281.
2. Kluin PM, Feller A, Gaulard P, et al. Peripheral T/NK-cell lymphoma: a report of the IXth workshop of the European association for haematopathology. Histopathology. 2001;38: 250-270.
3. Kaplan J, Ravindranath Y. Inoue S T-cell acute lymphoblastic leukemia with natural killer cell phenotype. Am J Hematol. 1986;22:355-364.
4. Koizumi S, Seki H, Tachinami T, et al. Malignant clonal expansion of large granular lymphocytes with a Leu-11+, Leu-7- surface phenotype: in vitro responsiveness of malignant cells to recombinant human interleukin 2. Blood. 1986;68: 1065-1073.
5. Pirruccelo SJ, Bicak MS, Gordon BG, et al. Acute lympho-blastic leukemia of NK-cell lineage: responses to IL-2. Leuk Res. 1989;13:735-743.
6. Imamura N, Kusunoki Y, Kawa-Ha K, et al. Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Haematol. 1990;75:49-59.
7. Ichikawa M, Kawai H, Komiyama A, et al. Functional p75 interleukin-2 receptor expression on the fresh blast cells in childhood acute lymphoblastic leukemia with natural killer cell properties. Am J Hematol. 1991;36:259-264.
8. Gardiner CM, Reen DJ, O'Meara A. Recognition of unusual presentation of natural killer cell leukemia. Am J Hematol. 1995;50:133-139.
9. Ohnuma K, Toyoda Y, Nishihira H, et al. Aggressive natural killer (NK) cell lymphoma: report of a pediatric case and review of the literature. Leuk Lymphoma. 1997;25: 387-392.
10. Manabe A, Takahashi K, Shibata R, et al. Long-term remission induced by corticosteroids, cyclophosphamide, and methotrexate in a patient with natural killer cell leukemia. Med Pediatr Oncol. 2000;34:224-225.
11. DuBois SG, Etzell JE, Matthay KK, et al. Pediatric acute blastic natural killer leukemia. Leuk Lymphoma. 2002;43: 901-906.
12. Yoshimasu T, Manabe A, Tanaka R, et al. Successful treatment of relapsed blastic natural killer cell lymphoma with unrelated cord blood transplantation. Bone Marrow Transplant. 2002;30:41-44.
13. Hyakuna N, Toguchi S, Higa T, et al. Childhood blastic NK cell leukemia successfully treated with L-asparaginase and allogenic bone marrow transplantation. Pediatr Blood Cancer. 2004;42:631-634.
14. Kern WF, Spier CM, Hanneman EH, et al. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement (see comments). Blood. 1992;79:2432.
15. Wong KF, Chan JK, Ng CS, et al. CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum Pathol. 1992; 23:798.
16. Jaffe ES, Chan JK, Su IJ, et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: definitions, differential diagnosis and epidemiology. Am J Surg Pathol. 1996;20:103-111.
17. Harris NL, Jaffe ES, Diebold J, et al. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie house, Virginia, November 1997. J Clin Oncol. 1999; 12:3835-3849.
18. Porcu P, Baiocchi RA, Magro C. Recent developments in the biology and therapy of T-cell and natural killer-cell lympho-mas. Curr Opin Oncol. 2003;15:353-362.
19. Ko YH, Cho EY, Kim JE, et al. Ree HJNK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status. Histopathology. 2004;44:480-489.
20. Lee J, Kim WS, Park YH, et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer. 2005;92:1226-1230.
21. Chan JKC, Jaffe ES, Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, eds. Pathology and Genetics - Tumors of Hematopoietic and Lymphoid Tissue. Lyon: IARC Press; 2001:204-207.
22. MacDonald HR, Schümann J. The need for natural killer T cells. Nat Med. 2005;11:256-257.
23. Jaffe ES, Krenacs L, Kumar S, Kingma DW, Raffeld M. Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol. 1999;111 (suppl 1):S46-S55.
24. +, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol. 2001;19:2179-2188.
25. Nakamura S, Katoh E, Koshikawa T, et al. Clinicopathologic study of nasal T/NK-cell lymphoma among the Japanese. Pathol Int. 1997;47:38-53.
26. Chang KL, Weiss LM. The association of the Epstein-Barr virus with malignant lymphoma. Biomed Pharmacother. 1996; 50:459-467.
27. Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/ T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005;41: 1402-1408.
28. Wong KF, Chan JKC, Lo ESF, et al. A study of the possible etiologic association of Epstein-Barr virus with reactive hemophagocytic syndrome in the Hong Kong Chinese. Hum Pathol. 1996;27:1239.
29. Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood. 1990;75: 434-444.
30. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis. 2000;6:601-608; Review.
31. Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int J Hematol. 1997;66:135-151; Review.
32. Majluf-Cruz A, Sosa-Camas R, Perez-Ramirez O, et al. Hemophagocytic syndrome associated with hematological neoplasias. Leuk Res. 1998;22:893-898.
33. Tong H, Ren Y, Liu H, et al. Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma. 2008;49:81-87.
34. Han AR, Lee HR, Park BB, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol. 2007;86:493-498.
35. Yong W, Zheng W, Zhu J, et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol. 2006; 24:28-32.